Drugs / REGN7508
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07759167 | Sep 2026 → Apr 2027 expected | end stage renal failure | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06444178 | Sep 2024 → Apr 2025 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05603195 | Jan 2023 → Sep 2024 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT07175428 | Oct 2025 → Feb 2027 expected | atrial fibrillation | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06299111 | Sep 2024 → Mar 2026 | venous thromboembolism | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT06454630 | Jun → Nov 2024 | venous thromboembolism | Regeneron Pharmaceuticals | Completed | Met primary |
| Phase 38 trials | ||||||
| Phase 3 | NCT07697599 | Sep 2026 → Jun 2029 expected | venous thromboembolism | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07493304 | Aug 2026 → Jul 2031 expected | venous thromboembolism | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07626411 | Aug 2026 → Sep 2029 expected | atrial fibrillation | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07318610 | Jul 2026 → Aug 2029 expected | peripheral arterial disease | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07430956 | Apr 2026 → Mar 2029 expected | atrial fibrillation | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07410117 | Mar 2026 → Jan 2030 expected | — | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07213778 | Nov 2025 → May 2027 expected | venous thromboembolism | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07015905 | Jun 2025 → Feb 2027 expected | venous thromboembolism | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-11-08 | Regeneron Pharmaceuticals | Results Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet regeneron.com ↗
As published and presented, the results showed that both REGN7508Cat and REGN9933A2 demonstrated clear efficacy for VTE prevention following total knee replacement surgery. |
| 2024-12-19 | Regeneron Pharmaceuticals | Results Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results regeneron.com ↗
Per the Phase 2 results, there was a robust antithrombotic effect for each antibody, and no clinically relevant bleeding was observed in any treatment arm. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-08 | Regeneron Pharmaceuticals | Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet regeneron.com ↗ |
| 2024-12-19 | Regeneron Pharmaceuticals | Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results regeneron.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN7508 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07493304 ↗ |
| Known as | cenvacibart | “Anticoagulation with mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat).” PMID 42275249 ↗ Jun 2026 |
| Known as | REGN7508Cat | “Anticoagulation with mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat).” PMID 42275249 ↗ Jun 2026 |
| Action | Inhibit | “Cenvacibart (REGN7508Cat) targets the catalytic domain to completely block FXI activity” PMID 42275249 ↗ Jun 2026 |
| Modality | Monoclonal antibody | “A Phase 2, Multicenter, Randomized, Open-Label, Active Control Study of REGN7508, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective,...” NCT06454630 ↗ |
| Route | Intravenous | “Administered sequential, ascending single intravenous (IV) dose” NCT05603195 ↗ |
| Target | F11 | “REGN7508, a Factor XI Monoclonal Antibody” NCT07213778 ↗ |